U.S. Rescheduling of Cannabis-Based Medicines May Boost IPOs and Private Funding for Cannabis Companies
U.S. rescheduling of cannabis-based medicines is expected to ease restrictions and stigma, potentially unlocking private funding and public market opportunities for cannabis companies. Ananda Pharma plans to raise $10 million to $20 million in private funding, while legal experts anticipate increased capital flow for cannabis businesses following the policy change.
Topics: cannabis-based drugs IPOs medical marijuana private funding U.S. regulatory changes